A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Conditions: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Interventions: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology & Blood Diseases Hospital; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Condition: Haploidentical Hematopoietic Stem Cell Transplantation Intervention: Drug: ATG-LDPTCy Sponsor: Samsung Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Conditions: Thalassemia, Beta; Thalassemia Major Intervention: Biological: VGB-Ex01 Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Shanghai Vitalgen BioPharma Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
